Sitaxentanpopulationen omfattede også patienter (N=53), hvor behandling med en anden endothelinreceptor- antagonist var seponeret pga. leverfunktionsabnormiteter.
The Sitaxentan population also included patients (N = 53) who had discontinued another endothelin receptor antagonist due to liver function abnormalities.